Dr. Tina Cascone with an insightful discussion on the MATISSE trial at #AACR26 plenary session. Outlines the current state of neoadjuvant and perioperative immunotherapy for NSCLC. A multitude of options now available demonstrating improved pCR, EFS, and OS fof resectable NSCLC. https://t.co/hX3rb6V6uQ